MetaVia Inc. financial data

Symbol
MTVA on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Concord Avenue, Suite 210, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
NeuroBo Pharmaceuticals, Inc. (to 11/18/2024), Gemphire Therapeutics Inc. (to 12/31/2019)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 246 % -42.4%
Debt-to-equity 68.7 % +122%
Return On Equity -221 % -272%
Return On Assets -131 % -189%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.65M shares +76.4%
Common Stock, Shares, Outstanding 8.64M shares +76.1%
Entity Public Float 13.8M USD +100%
Common Stock, Value, Issued 9K USD +80%
Weighted Average Number of Shares Outstanding, Basic 7.76M shares +53%
Weighted Average Number of Shares Outstanding, Diluted 7.76M shares +53%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 7.26M USD +7.85%
Costs and Expenses 28.8M USD +81.3%
Operating Income (Loss) -28.8M USD -81.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.6M USD -121%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.6M USD -121%
Earnings Per Share, Basic -3.56 USD/shares -44.7%
Earnings Per Share, Diluted -3.56 USD/shares -44.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16M USD -28.6%
Other Assets, Current 508K USD
Assets, Current 16.1M USD -28.6%
Property, Plant and Equipment, Net 34K USD -26.1%
Operating Lease, Right-of-Use Asset 133K USD -34.2%
Other Assets, Noncurrent 21K USD 0%
Assets 16.3M USD -28.6%
Accounts Payable, Current 3.88M USD +372%
Employee-related Liabilities, Current 713K USD +504%
Accrued Liabilities, Current 3.95M USD +847%
Liabilities, Current 8.27M USD +38.8%
Operating Lease, Liability, Noncurrent 58K USD -57.4%
Liabilities 8.33M USD +36.6%
Retained Earnings (Accumulated Deficit) -136M USD -25.5%
Stockholders' Equity Attributable to Parent 7.93M USD -52.5%
Liabilities and Equity 16.3M USD -28.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.44M USD -153%
Net Cash Provided by (Used in) Investing Activities -5K USD -25%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 8.64M shares +76.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16M USD -28.6%
Deferred Tax Assets, Valuation Allowance 16.1M USD +109%
Deferred Tax Assets, Gross 16.1M USD +109%
Operating Lease, Liability 136K USD -33%
Depreciation 5K USD +400%
Payments to Acquire Property, Plant, and Equipment 5K USD +25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.7M USD -134%
Lessee, Operating Lease, Liability, to be Paid 149K USD -36.6%
Property, Plant and Equipment, Gross 88K USD +10%
Operating Lease, Liability, Current 78K USD +16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60K USD -32.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 89K USD +3.49%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13K USD -59.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 60K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.96M USD +135%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 144M USD +15.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 37K USD -26%
Share-based Payment Arrangement, Expense 538K USD +142%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%